- Prev. close
- ¥5,816
- Volume
- 3.7M
Stock and sector context
Healthcareoutflow- Sector comparison
- Takeda Pharmaceutical changed +0.46%. The 3 covered Healthcare stocks in Japanese averaged -0.71%, with estimated sector flow of outflow.
- Variables to watch
- Drug approvals and trial resultsDrug pricing policyUS interest ratesUSD/JPY
- Risks to check
- Near the 52-week high, so profit-taking can appear
- Clinical trial failure
- Drug pricing pressure
This compares price changes among covered stocks in the same market. It does not establish why prices moved. Variables and risks are sector reference lists.
Why a candidate
Match 22/100The match score marks how many conditions overlap on a 0 to 100 scale: the 52-week range, valuation metrics, price change and volume. It is not a probability of rising or a forecast return.
Today's read
Takeda Pharmaceutical scores 22 out of 100 on today's InverseOne match ranking, 23 of 30 in the Japanese large-cap universe. It sits in the bottom 90% of its one-year price range, a neglected zone. Today's move of +0.46% came with money flowing in, alongside the Healthcare sector. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.
Data basis: 2026-10-09 close, 10-14 00:20 KST updated, For reference only, not advice
Same-sector stocks, Healthcare
Talk about this stock
Today's talking points
- It sits close to its 52-week high (90).
Three months out, which way do you see it?
Nobody has answered yet. Sign in to be the first.
These are answers picked by members, not investment advice.
These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.